Menu

rss
Thorax 67:391 doi:10.1136/thoraxjnl-2011-201189
  • Miscellaneous
  • Journal club

Azithromycin 250 mg daily reduces exacerbation frequency and improves quality of life in selected COPD patients

  1. K D S Pannu
  1. Correspondence toDr K D S Pannu, ST5, Respiratory Medicine, Basildon University Hospital, Nethermayne, Basildon SS16 5NL, UK; kds_pannu{at}yahoo.com

This multicentre study randomised 1142 subjects at risk of acute exacerbations of chronic obstructive pulmonary disease (COPD) to receive azithromycin 250 mg daily (n=570) or placebo (n=572) for 1 year, in addition to usual care. The enrolled subjects were allowed to continue on inhaled treatments and/or oxygen. None of the subjects were on oral theophylline. The primary outcome, time …

[Full text of this article]

This Article

  1. Extract
  2. Full text
  3. PDF
  4. All Versions of this Article:
    1. thoraxjnl-2011-201189v1
    2. 67/5/391 most recent

Social bookmarking


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Thorax.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.